Our study demonstrated that ropivacaine was capable of inhibiting cell viability and enhancing apoptosis in HepG2 cells, and the potential anticancer mechanism of ropivacaine in hepatocellular carcinoma may involve the IGF-1 R/PI3K/AKT/mTOR axis. Here, AKT1 is linked to hepatocellular carcinoma.